Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881107083838v1
22/3/300    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Norman, C.
Right arrow Articles by Bennett, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Norman, C.
Right arrow Articles by Bennett, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on May 1, 2008
Journal of Psychopharmacology, Vol. 22, No. 3, 300-307 (2008)
DOI: 10.1177/0269881107083838

Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion

C. Norman

Division of Psychology, Nottingham Trent University, Burton Street, Nottingham, UK, christine.norman{at}ntu.ac.uk

Srg Beckett

Institute of Neuroscience, Medical School, Queen's Medical Centre, University of Nottingham, Nottingham, UK

CH Spicer

Institute of Neuroscience, Medical School, Queen's Medical Centre, University of Nottingham, Nottingham, UK

D. Ashton

Johnson and Johnson Pharmaceutical R&D, Turnhoutseweg, Beerse, Belgium

X. Langlois

Johnson and Johnson Pharmaceutical R&D, Turnhoutseweg, Beerse, Belgium

GW Bennett

Institute of Neuroscience, Medical School, Queen's Medical Centre, University of Nottingham, Nottingham, UK

Neurotensin (NT) has been proposed as an endogenous antipsychotic based in part on the similarity in behavioural effects to antipsychotic drugs, for example, attenuation of both amphetamine-induced hyperlocomotion (AH) and amphetamine disrupted pre-pulse inhibition in the rat. However, there is some evidence that repeated administration of NT or an analogue produces behavioural tolerance to such effects. The present experiments sought to confirm and extend these findings by testing the effects on AH of 7 days central administration of NT and the NT 1 selective analogue PD 149163 and the effects of 21 days central administration of NT. NT and PD149163 continuously administered for 7 days produced no effect on AH (in contrast to attenuation with a single injection here and previously reported), whereas 21 days of NT administration potentiated AH. Together, these studies report that the effects of NT or a NT analogue on AH depends on the duration of administration of peptide. The results are discussed in comparison with the reported antipsychotic properties of acute administration of NT and possible mechanisms involving NT1 receptors.

Key Words: amphetamine • antipsychotic • chronic • locomotion • rat • schizophrenia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?